Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol in non-alcoholic fatty liver disease
IRCT20180404039187N2Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of allopurinol in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Tabriz University of Medical Sciences. Started Jan 2017; status: completed.
02
Drugs
allopurinol
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20180404039187N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180404039187N2.